Substituted nucleoside analogs as PRMT5 inhibitors
The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
1 . A compound of formula (III), its stereoisomer, or its pharmaceutically acceptable salt,
wherein the compound is (1S,2R,5R)-3-(2-(2-Amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol.
2 . A pharmaceutical composition comprising the compound of claim 1 , its stereoisomer, or its pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.
3 . A method for treating a disease, disorder, syndrome or condition associated with PRMT5 enzyme, comprising administering to a subject in need thereof an effective amount of the compound as claimed in claim 1 .
4 . A method as claimed in claim 3 , wherein the said disease, disorder, syndrome, or condition associated with PRMT5 enzyme is glioblastoma multiforme, prostate cancer, pancreatic cancer, mantle cell lymphoma, non-Hodgkin's lymphomas and diffuse large B-cell lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, non-small cell lung cancer, small cell lung cancer, breast cancer, triple negative breast cancer, gastric cancer, colorectal cancer, ovarian cancer, bladder cancer, hepatocellular cancer, melanoma, sarcoma, oropharyngeal squamous cell carcinoma, chronic myelogenous leukemia, epidermal squamous cell carcinoma, nasopharyngeal carcinoma, neuroblastoma, endometrial carcinoma, and cervical cancer.
5 . A method as claimed in claim 3 , wherein the said disease, disorder, syndrome, or condition associated with PRMT5 enzyme is cancer.